The U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense (DOD), announced that it secured 3.2 million doses of Novavax’s COVID-19 vaccine. The protein-based, adjuvanted vaccine will be made available for free to states, jurisdictions, federal pharmacy partners, and FQHCs if it receives U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and recommendation from the Centers for Disease Control and Prevention (CDC). The company is expected to complete all necessary quality testing in the next few weeks, which would support the final release of the product.
